Yesterday, the Co-President and SVP of Dynavax (DVAX), David Novack, bought shares of DVAX for $50K.
This recent transaction increases David Novack’s holding in the company by 16.37% to a total of $398.1K. This is Novack’s first Buy trade following 3 Sell transactions.
See today’s analyst top recommended stocks >>
Based on Dynavax’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $8.3 million and GAAP net loss of $42.71 million. In comparison, last year the company earned revenue of $1.25 million and had a GAAP net loss of $39.44 million. Currently, Dynavax has an average volume of 2.31M. The Company has a Price to Book ratio of 20.6757.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $16.00, reflecting a 376.2% upside. Starting in October 2018, DVAX received 23 Buy ratings in a row. Four different firms, including Cantor Fitzgerald and Cowen & Co., currently also have a Buy rating on the stock.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body’s innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases.
